Gufic Biosciences Ltd (GUFICBIO) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Gufic Biosciences Ltd on NSE and BSE, with an AI summary of each filing.
Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is attached herewith
Others (Uncategorized) · 05 Nov 2026, 12:07 am
ITAT Remands Gufic Biosciences Tax Assessment for AY2023-24 to Assessing Officer Gufic Biosciences received an order dated 15th Oct'26 from ITAT Mumbai regarding AY23-24 assessment. Originally, an assessment order dated 18th Mar'25 levied a tax demand of Rs. 11.89 cr, later reduced to Rs. 11.76 lakh by CIT(A). Following appeals by both the Income Tax Department and the company, ITAT set aside CIT(A)'s findings and remanded the matter back to the Assessing Officer for fresh consideration. The ruling creates no immediate financial demand or operational impact; final tax liability will depend on fresh assessment outcomes.
Intimation regarding USFDA Pre-Approval Inspection at the Company''s Manufacturing facility situated at Indore, Madhya Pradesh is attached herewith.
Others (Uncategorized) · 24 Oct 2026, 2:11 am
USFDA Issues Three Form 483 Observations for Gufic Biosciences' Indore Facility The USFDA conducted a Pre-Approval Inspection (PAI) at Gufic Biosciences Limited's manufacturing facility located in Indore, Madhya Pradesh, from 15th Oct'26 to 23rd Oct'26. Upon concluding the inspection, the regulator issued Form FDA 483 with three observations. The company stated it will work closely with the USFDA and remains committed to addressing all observations comprehensively within the stipulated timeframe.
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is attached herewith
Others (Uncategorized) · 30 Sept 2026, 12:15 am
Gufic Biosciences Wins Tax Appeal Deleting Rs 4.33 Crore Demand Gufic Biosciences Limited received an appellate order on 29th Sep'26 from the Commissioner of Income Tax (Appeals), dated 28th Sep'26, under Section 250 of the Income Tax Act, 1961. The appellate authority ruled in favor of the company, allowing its appeal against an income tax demand of Rs. 4,33,36,680 for Assessment Year 2024-25, which originally arose from expenditure disallowances under Section 143. Once given effect, this order will result in the complete deletion of the Rs. 4.33 crore tax liability.
Intimation of Environmental, Social and Governance (''ESG'') Rating is attached herewith
Others (Uncategorized) · 28 Sept 2026, 11:52 pm
Gufic Biosciences Secures Strong CRISIL ESG Rating of 62 Crisil ESG Ratings & Analytics has assigned an overall rating of CRISIL ESG 62 (Category: Strong) to Gufic Biosciences Limited for FY25-26. The evaluation was conducted independently based on publicly available domain information, as the company did not officially engage Crisil for the rating process. The rating report, dated 25th Sep'26, was received and disclosed by the company on 28th Sep'26 in compliance with SEBI listing regulations.
Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is attached herewith
Others (Uncategorized) · 24 Sept 2026, 8:55 pm
Gufic Biosciences Faces Rejection of NSE Penalty Waiver Application NSE has rejected Gufic Biosciences' waiver application regarding a penalty of ₹1,72,000 (excluding GST) levied for non-compliance with Regulation 17(1A) of SEBI LODR during the quarter ended Sep'24. The violation pertained to appointing an Independent Director aged above 75 years without prior shareholder approval via a special resolution. The company previously paid ₹8,000 each to BSE and NSE for Jun'24, while BSE rejected its waiver on 13th Mar'26. Gufic will pay the pending ₹1,72,000 fine to NSE by 3rd Oct'26.
Intimation of Credit Rating is attached herewith
Others (Uncategorized) · 09 Sept 2026, 12:21 am
CRISIL Reaffirms Credit Ratings for Gufic Biosciences' Enhanced Bank Facilities CRISIL Ratings has reaffirmed its credit ratings on the bank facilities of Gufic Biosciences Limited. The company's total rated bank loan facilities have been enhanced to Rs. 516 Crore from Rs. 425 Crore. CRISIL reaffirmed the long-term rating at 'CRISIL A-/Stable' and the short-term rating at 'CRISIL A2+', reflecting sustained operational stability and creditworthiness across its enhanced borrowing limits.
Voting Results and Consolidated Scrutinizer Report of 42nd Annual General Meeting of the Company held on Friday, September 04, 2026 is attached herewith
Annual General Meeting · 08 Sept 2026, 12:56 am
Proceedings of the 42nd Annual General Meeting of the Company held on Friday, September 04, 2026 is attached herewith
Annual General Meeting · 05 Sept 2026, 1:11 am
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Promotion and Change in Designation of Senior Management Personnel is attached herewith
Change in Management · 03 Sept 2026, 12:02 am
Gufic Biosciences Announces Key Senior Management Promotions in Legal and Sales Gufic Biosciences announced key senior management promotions effective 2nd Sep'26. Pinak Padhya is elevated to President of Sales & Marketing from Vice President, leveraging 28 years of commercial experience across major pharma firms like Sun Pharma and Glenmark to drive strategic brand building and market expansion. Concurrently, Ami Shah is promoted to Head-Legal, retaining her core responsibilities as Company Secretary and Compliance Officer. These internal elevations aim to strengthen Gufic’s corporate governance framework and commercial leadership to support continued business growth.
Written Transcript of Earnings Conference Call held on August 17, 2026 at 04:30 p.m. is attached herewith
Transcript · 21 Aug 2026, 10:44 pm
Intimation of Audio Recording of Earnings Conference Call held on August 17, 2026 at 04:30 p.m. is attached herewith
Audio / Video · 18 Aug 2026, 12:01 am
Gufic Biosciences Publishes Earnings Call Audio Recording Gufic Biosciences (NSE: GUFICBIO) has uploaded the audio recording of its earnings conference call held on 17 Aug'26 at 4:30 PM. The recording is available on the company's website. This action complies with SEBI's Listing Obligations and Disclosure Requirements, 2015. A written transcript of the call will be submitted separately in due course. This filing provides stakeholders access to management's discussion on recent performance and outlook, ahead of the official transcript release.
Investor Presentation for the Quarter ended June 30, 2026 is attached herewith
Investor Presentation · 15 Aug 2026, 1:47 am
Gufic Biosciences Q1 FY27: Strong Growth and Margin Expansion Gufic Biosciences reported strong Q1 FY27 results with revenue of Rs. 260.8 Cr, up 14.8% YoY, and PAT of Rs. 22.0 Cr, up 81.8% YoY. EBITDA margin expanded 349 bps YoY to 18.09%, driven by a favorable product mix. The Indore plant is on track, having completed its EU audit with certification awaited, and is expected to drive future growth as it nears 30% utilization by FY26. The company launched AWABAC, a first-in-India anti-infective, and is advancing its Botulinum Toxin franchise, holding a number two market position.
Approval for Incorporation of Subsidiary in the Philippines and Investment by way of Subscription to its Equity Share Capital is attached herewith.
Others (Uncategorized) · 15 Aug 2026, 1:35 am
Gufic Biosciences to Expand in Philippines with New Subsidiary Gufic Biosciences' board approved on 14 Aug'26 the incorporation of a subsidiary in the Philippines to expand its business presence. The new entity, Gufic Philippines Inc., will market, sell, and distribute the company's pharmaceutical products. Gufic will invest up to USD 250,000 via cash subscription for an approximate 99.99% equity stake, giving it full control. This strategic move aims to facilitate business expansion and manage intellectual property rights in the region. The incorporation is expected within 12 months, pending regulatory approvals.
Unaudited Financial Results (Standalone and Consolidated) for the Quarter ended June 30, 2026 is attached herewith.
Financial Result · 15 Aug 2026, 1:15 am
Gufic Bio Reports Q1FY27 Results and Philippines Expansion Gufic Biosciences reported Q1FY27 consolidated net profit of ₹22.31 crore, up 72.3% YoY. Revenue from operations for the quarter ended 30 Jun'26 grew 16.6% YoY to ₹260.82 crore. The company's board also approved the incorporation of a new subsidiary, Gufic Philippines Inc., to expand its pharmaceutical business. This strategic move involves an investment of up to USD 250,000 for an approximate 99.99% stake, aiming to market, sell, and manage intellectual property rights in the Philippines.
Outcome of the Board of Directors Meeting held on Friday, August 14, 2026 is attached herewith.
Outcome · 15 Aug 2026, 1:03 am
Gufic Biosciences Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) ■ Revenue: 26,082 (+16.6% YoY | +3.6% QoQ) ■ EBITDA: 4,661 (+40.0% YoY | -1.3% QoQ) ■ EBITDA Margin (%): 17.9 (+298 bps YoY | -88 bps QoQ) ■ PAT: 2,231 (+70.7% YoY | +1.9% QoQ) ■ EPS (INR): 2.22 (+70.8% YoY | +1.8% QoQ)
Business Responsibility and Sustainability Report for the Financial Year ended March 31, 2026, is attached herewith
Others (Uncategorized) · 13 Aug 2026, 3:24 am
Gufic Biosciences FY26 Business Responsibility & Sustainability Report Gufic Biosciences reported a turnover of ₹940.48 Cr and net worth of ₹664.18 Cr for FY26. Exports contributed 23.07% to total turnover, serving over 70 countries. For FY26, the permanent employee turnover rate was 20.73%, slightly down from 21.40% in FY25. Accounts payable days improved to 98.65 from 103.68. Investments in related parties were 37.85% of total investments. Scope 1 and 2 GHG emissions were 25,464 MTCO2e. The company reported 3 shareholder and 29 product-related complaints, all resolved by year-end.
Annual Report for the Financial Year 2025-2026 alongwith Notice of 42nd Annual General Meeting is attached herewith.
Others (Uncategorized) · 13 Aug 2026, 3:12 am
Intimation for book closure and record date for the purpose of 42nd Annual General Meeting and payment of final dividend for the financial year ended March 31, 2026
Dividend · 13 Aug 2026, 2:56 am
Intimation of 42nd Annual General Meeting, is attached herewith
Annual General Meeting · 13 Aug 2026, 2:52 am
Intimation of Earnings Conference Call scheduled to be held on August 17, 2026 is attached herewith
Intimation · 17 Aug 2026, 4:30 pm
Gufic Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Unaudited Financial Results ....
Intimation · 14 Aug 2026, 5:30 am
Gufic Biosciences Board Meeting Set for Q1 FY27 Results Approval Gufic Biosciences has scheduled a Board of Directors meeting for 14 Aug '26 to consider and approve its Unaudited Financial Results (Standalone and Consolidated) for the quarter ending 30 Jun '26. The trading window for designated persons, which closed on 26 Jun '26, will remain shut until 48 hours after the financial results are declared. This action is in accordance with SEBI's insider trading regulations. Investors should monitor the outcome for key performance metrics and future outlook.
Intimation for Re-appointment of Mr. Pankaj Jayakumar Gandhi (DIN: 00001858) as the Whole Time Director of the Company is attached herewith.
Change in Management · 01 Aug 2026, 1:10 am
Gufic Biosciences Re-Appoints Pankaj Gandhi as Whole Time Director Gufic Biosciences' board approved the re-appointment of Mr. Pankaj Jayakumar Gandhi as Whole Time Director on 31st Jul'26. The new five-year term is effective from 07th Sep'26 to 06th Sep'31, contingent on shareholder approval at the upcoming 42nd AGM. Mr. Gandhi brings over three decades of pharmaceutical industry experience, specializing in regulatory compliance and liaison. He is not related to any other directors on the board. The company confirmed he is not debarred by SEBI or any other authority.
Outcome of the Board of Directors Meeting held on Friday, July 31, 2026 is attached herewith
Others (Uncategorized) · 01 Aug 2026, 1:03 am
Gufic Biosciences Approves Re-appointment of Whole Time Director for Five Years The Board of Directors on 31st Jul'26 approved the re-appointment of Mr. Pankaj Jayakumar Gandhi as Whole Time Director. The new five-year term is effective from 07th Sep'26 to 06th Sep'31, pending shareholder approval at the upcoming 42nd AGM. Mr. Gandhi brings over three decades of pharmaceutical industry experience, specializing in regulatory compliance and liaison. The company confirmed he is not debarred by any regulatory authority and has no relationships with other board members, ensuring leadership continuity.
Written Transcript of Earnings Conference Call held on June 01, 2026 at 04:30 PM is attached herewith.
Transcript · 05 Jun 2026, 11:43 pm
Corrigendum and Clarification to Intimation dated May 29, 2026 regarding Subscription to Shares of Saraswat Co-operative Bank Limited, is attached herewith
Others (Uncategorized) · 02 Jun 2026, 8:57 pm
Gufic Biosciences Clarifies Share Subscription in Saraswat Co-operative Bank Gufic Biosciences clarified on 02 Jun'26 that its subscription to shares of Saraswat Bank is a regulatory requirement for its existing ₹230 crore credit facility. This action is a share-linkage obligation for borrower members, not an ownership stake acquisition. The transaction adheres to RBI norms permitting linkage up to 2.5% of secured borrowings for co-operative banks. It does not alter management control or confer additional voting rights, maintaining the "one member, one vote" principle. Other details from the 29 May'26 disclosure remain unchanged.